Back to top
more

Evofem Biosciences (EVFM)

(Delayed Data from OTC)

$0.01 USD

0.01
557,964

0.00 (0.72%)

Updated May 7, 2024 02:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (74 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Brokerage Reports

0 items in cart

Evofem Biosciences, Inc. [EVFM]

Reports for Purchase

Showing records 61 - 80 ( 118 total )

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 61

11/07/2019

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 62

11/05/2019

Company Report

Pages: 11

Takeaways from our Expert Call with Russ Barrans - Fred Wilkinson

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 63

11/05/2019

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 64

10/28/2019

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 65

10/25/2019

Company Report

Pages: 9

Takeaways from our Expert Call with Dr. Lisa Rarick

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 66

10/23/2019

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 67

10/22/2019

Company Report

Pages: 8

Game Plan on Making Amphora into a Blockbuster Contraception

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 68

10/17/2019

Company Report

Pages: 5

Surveillance Report Indicates Sexually Transmitted Infections on the Rise; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 69

09/17/2019

Industry Report

Pages: 9

Healthcare Additional Doc Calls to Pricing

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 70

09/03/2019

Industry Report

Pages: 7

Healthcare- Join Our Doc Call Series on Drug Pricing

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 71

08/28/2019

Company Report

Pages: 5

AMPREVENCE Trial Completed; Top-Line Data in November; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 72

08/15/2019

Industry Report

Pages: 4

Healthcare - Earnings Recap: The More Analysis, The Merrier, Especially When Data-Driven

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 73

08/07/2019

Company Report

Pages: 5

2Q19 Financial Results Reported; All Eyes on Amphora; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 74

08/07/2019

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 75

08/07/2019

Company Report

Pages: 12

2Q19 - Let''s Dig Deep and Figure Out Amphora''s Commercial Fate

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 76

06/12/2019

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 77

06/12/2019

Daily Note

Pages: 4

With $80M Capital Raise Secured, Potential Launch in 2Q20 Is Within Reach

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 78

05/28/2019

Company Report

Pages: 4

1Q19 Financial Results Reported; Amphora Filing Near Term; Reiterate Buy and Modulating Target to $9

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 79

05/21/2019

Industry Report

Pages: 3

Healthcare -Recap of 22 Expert Calls in 2018 - 2019 for Our Coverage Universe

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 80

05/21/2019

Industry Report

Pages: 3

Recap of 22 Expert Calls in 2018 - 2019 for Our Coverage Universe

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party